Further, Quintanal-Villalonga and his colleagues found that highly-expressed FGFR1 may result in a higher resistance to EGFR-TKI in the patients with EGFR-mutated lung cancer and those patients may benefit from combined EGFR/FGFR inhibition (Quintanal-Villalonga et al., 2019). The gene discussed is EGFR; the disease is lung carcinoma.